Joaquina Baranda, MD

Dr. Baranda received her medical degree from the University of Santo Thomas in the Philippines in 1985 and completed her residency in internal medicine at Cook County Hospital in Chicago. Prior to joining KU Cancer Center she was an assistant professor at the University of Southern California Norris Comprehensive Cancer Center as a GI oncologist, specialty care physician at Kansas City Veterans Administration Medical Center and medical director of clinical development and medical affairs at a biotech company as the medical lead for multi-center phase I trials.

She is an active member of the Society for Immunotherapy in Cancer, European Society of Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO).

Joaquina Baranda, MD, focuses her research on drug development and early therapeutics through investigator initiated trials, national and industry sponsored trials. She has served as the principal investigator in phase I, II and III clinical trials in gastrointestinal cancers and later as an early phase investigator in different malignancies. Dr. Baranda is one of the leaders in translational clinical trial development at KU Cancer Center and nationally through the Southwest Oncology Group (now known as SWOG) with active roles in the GI working group.

Dr. Baranda leads the Early Phase research unit at KU Cancer Center with the goal of increasing patient access to novel agents and developing translational investigations with biomarker development leading to precision medicine. She is the co-chair of the KU Cancer Center Investigator Initiated Trial Executive Committee. For many years she served as Chair of KU Cancer Center’s Cancer Program Education Committee, the Multidisciplinary Tumor Conference and was leader of GI oncology.

A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors.

A Phase 1b study of PEGPH20 plus pembrolizumab in patients with selected hyaluronan-high solid tumors

A window of opportunity trial of atorvastatin in p53-mutant and p53 wild type malignancies

A Window of Opportunity Trial Using Intratumoral Injection of Glatiramer as an Immune Modulator in Patients with Resectable Head and Neck and Cutaneous Squamous Cell Cancer

Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results.

Cemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from phase I cohorts

Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients.

Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort.

Clinical Outcome of Ampullary Carcinoma: Single Cancer Center Experience.

Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.

Enfortumab Vedotin (EV) in Patients (Pts) with Metastatic Urothelial Carcinoma (mUC) with Prior Checkpoint Inhibitor (CPI) Failure: A Prospective Cohort of an Ongoing Phase 1 Study

Equitable Access to Clinical Trials: How Do We Achieve It?

EV-101: A Phase 1 Study of Single-Agent Enfortumab Vedotin in Patients With Nectin- 4 Positive Solid Tumors Including Metastatic Urothelial Cancer

Expanding Access to Early Phase Trials: The CATCH-UP.2020 Experience.

Hematologic malignancies in temozolomide-treated metastatic pancreatic neuroendocrine tumors

Niraparib in metastatic pancreatic cancer after previous chemotherapy (NIRA-PANC): A phase 2 trial

Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors.

Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial

Safety, pharmacokinetic and pharmacodynamic results from dose escalation of SAR439459, a TGFβ inhibitor, as monotherapy or in combination with cemiplimab in a phase 1/1b study.

A PHASE 1 2, OPEN-LABEL, MUL TICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF NKTR-262 IN COMBINATION WITH BEMPEGALDESLEUKIN {NKTR-214) AND IN COMBINATION WITH BEMPEGALDESLEUKIN

A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults with Ovarian Cancer and other FOLR1-Positive Solid Tumors

A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer that Express Nectin-4

A Phase 1/2 Study of the Safety, Tolerability and Efficacy of INCB24360 Administered in Combination with Nivolumab in Select Advanced Cancers

A Phase II II Multi Center Randomized Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs ON 01910.Na Combined with Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Cancer

A Phase III Study of FOLFIRINOX With or Without HyperAcute-Pancreas (algenpantucel-L) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

MAVERICC*: A Randsomized Phase II Study of BEVACIZUMAB/mFOLFOX6 VS. BEVACIZUMAB/FOLFIRI with Biomarker Stratification in Patients with Previously Untreated Metastatic Colorectal Cancer

Multiple doses of Abemaciclib on the Pharmacokinetics of Cytochrome

Open-Label Trial with Mouse Renal Adenocarcinoma (RENCA) Cell-Containing Agarose-Agarose Macrobeads Compared with Best Supportive Care in Patients with Treatment-Resistant, Metastatic Colorectal Carcinoma

Ruxolitinib or Placebo in Combination with Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy

Study of Gemcitabine Abraxane Plus Placebo